Nkarta (NKTX) Stock Price, News & Analysis

Company Overview

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key Stats

• Today's Range: $1.74 to $1.79
• 50-Day Range: $1.66 to $2.12
• 52-Week Range: $1.31 to $8.23
• Volume: 274,388 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $124.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.33
• Consensus Rating: Buy

Nkarta Stock Analysis - MarketRank™

Nkarta scored higher than 46% of companies evaluated by MarketBeat, and ranked 1816th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Nkarta has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Nkarta has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nkarta are expected to decrease in the coming year, from ($1.70) to ($1.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nkarta is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nkarta is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nkarta has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.15% of the float of Nkarta has been sold short.

Short Interest Ratio / Days to Cover

Nkarta has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Nkarta has recently increased by 3.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nkarta does not currently pay a dividend.

Dividend Growth

Nkarta does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.15% of the float of Nkarta has been sold short.

Short Interest Ratio / Days to Cover

Nkarta has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Nkarta has recently increased by 3.13%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.25

News Sentiment

Nkarta has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Nkarta this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Nkarta to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nkarta insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.40% of the stock of Nkarta is held by insiders.

Percentage Held by Institutions

80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NKTX Stock Analysis - Frequently Asked Questions

How have NKTX shares performed this year?

Nkarta's stock was trading at $2.49 at the beginning of 2025. Since then, NKTX shares have decreased by 29.5% and is now trading at $1.7550.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.01.

When did Nkarta IPO?

Nkarta (NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO.

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NKTX
• CIK: 1787400
• Web: www.nkartatx.com
• Phone: 925-407-1049
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.33
• High Stock Price Target: $18.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +716.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$108.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.64%
• Return on Assets: -21.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.48
• Quick Ratio: 14.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.78 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 70,960,000
• Free Float: 64,998,000
• Market Cap: $124.53 million
• Optionable: Optionable
• Beta: 0.70